Algorae Wins TGA Dossier Acceptance for First Generic Medicine

Living Cell Technologies ( (AU:1AI) ) has shared an announcement.

Algorae Pharmaceuticals has had its initial registration dossier accepted for evaluation by Australia’s Therapeutic Goods Administration, marking an early but important milestone in progressing its first product toward potential commercialisation under the Algorae brand. The company emphasised that acceptance only confirms the dossier met preliminary requirements and does not foreshadow the outcome, but it plans to provide regular aggregated updates as the formal review advances.

The application relates to the first of seven generic medicines covered by AlgoraeRx’s licence and supply agreements with Sakar Healthcare and Cadila Pharmaceuticals for the Australian and New Zealand markets. This submission is also the first in a planned series of TGA filings across Algorae’s broader medicine portfolio, underscoring the company’s push to build a revenue-generating generic and specialty medicines pipeline alongside its AI-driven drug discovery activities.

The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals is an AI-enabled pharmaceutical company focused on drug-combination discovery and the commercialisation of generic and specialty medicines. Its proprietary AlgoraeOS platform uses artificial intelligence to identify synergistic drug combinations, while its AlgoraeRx division licenses and supplies medicines in Australia and New Zealand through manufacturing partners and established distribution channels.

YTD Price Performance: 28.57%

Average Trading Volume: 1,488,699

Technical Sentiment Signal: Buy

Current Market Cap: A$31.7M

See more insights into 1AI stock on TipRanks’ Stock Analysis page.